ORCID

Abstract

Aim: This subanalysis of the OPTIPARK study aimed to confirm the effectiveness and safety of opicapone in patients with Parkinson's disease and motor fluctuations in clinical practice specifically in the UK and to assess the impact of opicapone on treatment costs. Methods: Patients received opicapone added to levodopa for 6 months. Clinical outcomes were assessed at 3 and 6 months and treatment costs at 6 months. Results: Most patients' general condition improved at 3 months, with sustained improvements reported at 6 months. Opicapone improved motor and non-motor symptoms at both timepoints, was generally well tolerated and reduced total treatment costs by GBP 3719. Conclusion: Opicapone added to levodopa resulted in clinical improvements and reduced treatment costs across UK clinical practice.

Publication Date

2022-01-01

Publication Title

Neurodegenerative Disease Management

Volume

12

Issue

2

ISSN

1758-2024

Acceptance Date

2022-02-17

Deposit Date

2022-05-25

Embargo Period

2022-05-26

Funding

The study was funded by BIAL. P Soares-da-Silva was employed by the funder and participated in the study design, data collection, data management and data analysis. The funder of the study had no other role in data interpretation or in the decision to submit the manuscript for publication. KR Chaudhuri has served as an advisory board member for AbbVie, UCB, GKC, BIAL, Cynapsus Therapeutics, Lobsor Pharmaceuticals, STADA, Medtronic, Zambon, Profile, Sunovion, Roche, Theravance, Scion, Britannia, Acadia and 4D. He has received honoraria for lectures from AbbVie, Britannia, UCB, Zambon, Novartis, Boehringer Ingelheim, BIAL, Kyowa Kirin and SK Pharma. He has obtained investigator-initiated grants from Britannia, AbbVie, UCB, GKC and BIAL and academic grants from the EU, IMI EU, Horizon 2020, Parkinson’s UK, NIHR, PDNMG, EU (Horizon 2020), Kirby Laing Foundation, NPF, MRC and Wellcome Trust. He also reports royalties or licenses from Oxford and Cambridge publishers and the Mapi Institute (KPPS, PDSS 2) and payment for expert testimony from GMC. C Carroll has received a salary from University of Plymouth, University Hospitals Plymouth NHS Trust and National Institute of Health Research. She has also obtained advisory, consulting and lecture fees from AbbVie, BIAL, Lundbeck, Britannia, Global Kinetics and Medscape and research funding from Parkinson’s UK, National Institute of Health Research and Cure Parkinson’s. N Pavese has received advisory, consulting and lecture fees from BIAL, Britannia, Boston Scientific, Roche and Abbvie and research funding from Independent Research Fund Denmark, Danish Parkinson’s disease Association, Parkinson’s UK, Center of Excellence in Neurodegeneration (CoEN) network award, GE Healthcare Grant, Multiple System Atrophy Trust, EU Joint Program Neurodegenerative Disease Research (JPND), EU Horizon 2020 research and innovation programme, Italian Ministry of Health and the MJFF. J Evans has served as an advisory board member for BIAL. T Foltynie has received grants from National Institute of Health Research, Michael J. Fox Foundation, John Black Charitable Foundation, Cure Parkinson’s Trust, Innovate UK, Janet Owens Research Fellowship, Rosetrees Trust, Van Andel Research Institute and Defeat MSA. He has served on advisory boards for Peptron, Voyager Therapeutics, Handl Therapeutics, Veeva Systems, Inc., Living Cell Technologies, BIAL and Profile Pharma. He has received honoraria for talks sponsored by BIAL, Profile Pharma and Boston Scientific. H Reichmann participated on advisory boards, gave lectures and received research grants from Abbott, Abbvie, Bayer Health Care, BIAL, Boehringer/Ingelheim, Britannia, Cephalon, Desitin, GSK, Lundbeck, Medtronic, Merck-Serono, Novartis, Orion, Pfizer, TEVA, UCB, Valeant and Zambon. L Zurowska and P Soares-da-Silva are employed by BIAL. A Lees is funded by the Reta Lila Weston Institute of Neurological Studies, University College London, Institute of Neurology and reports consultancies from Britannia Pharmaceuticals and BIAL. He also reports grants and/or research support from the Frances and Renee Hock Fund and honoraria from Britannia Pharmaceuticals, Profile Pharma, UCB, Roche, BIAL, STADA, Nordiclnfu Care and NeuroDerm. C Schofield and JC Sharma have no conflict of interests to declare. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Editorial assistance for the development of this manuscript was funded by BIAL. Editorial assistance was provided by K Male from mXm Medical Communications.

First Page

77

Last Page

91

Download

Share

COinS